A new way to finance drug development, for rare disease and beyond with Alok Tayi | Podcast #28
Welcome to Talking Precision Medicine — the podcast in [...]
Xerna™ TME Panel as a predictive biomarker in lung cancer
Together with Exact Sciences and OncXerna Therapeutics, Genialis presented a [...]
SITC 2022: some thoughts in review
By Luka Ausec and Daniel Pointing Below are some observations, [...]
Genialis Presents New Clinical Biomarker Findings at SITC, BioTechX
I/ML technology used to enhance drug development included in [...]
A Novel Tumor Microenvironment Patient Classifier for Gastroesophageal Cancer
At ESMO 2022, Genialis co-authored a poster with collaborators from [...]
Genialis Updates ResponderID, Enhancing Data Flywheel for Improved Clinical Biomarker Discovery
AI/ML technology helps therapeutic companies improve likelihood of clinical [...]
What’s in a Name?: Endpoint Health’s Patient-Centric Northstar with Jason Springs | Podcast #27
Welcome to Talking Precision Medicine — the podcast in [...]
Genialis’ ResponderID™ Named a Fast Company 2022 World Changing Idea
The winners of Fast Company’s 2022 World Changing Ideas [...]
Genialis Renews ISO 27001 Certification for Fifth Year Running
Renewed credentials underscore the computational precision medicine company’s commitment to [...]
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.
